BI 1015550 Emerging Drug Insight

“BI 1015550 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about BI 1015550 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) in the seven major markets. A detailed picture of the BI 1015550 in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the BI 1015550. The report provides insights about the mechanism of action, dosage, and administration, as well as research and development, including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, including the BI 1015550 market forecast analysis in the 7MM, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies.

Drug Summary

BI 1015550 is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects being developed by Boehringer Ingelheim. It has the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function – and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs). BI 1015550 represents the first molecule in the class of PDE4B inhibitors that is being studied for IPF and other progressive fibrosing ILDs.

The accelerated development of BI 1015550 is part of Boehringer Ingelheim’s next wave of potential innovative treatments for interstitial lung diseases aimed at preserving lung function and improving the lives of patients. Recently, the promising 12-week data of Phase II showed a reduction in the rate of lung function decline in patients with IPF.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the BI 1015550 description, mechanism of action, dosage and administration, research and development activities in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• Elaborated details on BI 1015550 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the BI 1015550 research and development activities in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around BI 1015550.
• The report contains forecasted sales of for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• The report also features the SWOT analysis with analyst views for BI 1015550 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities' websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

BI 1015550 Analytical Perspective by DelveInsight

In-depth BI 1015550 Market Assessment

This report provides a detailed market assessment of BI 1015550 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of BI 1015550.

BI 1015550 Clinical Assessment

The report provides the clinical trials information of BI 1015550 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BI 1015550 dominance.
• Other emerging products for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) are expected to give tough market competition to BI 1015550, and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of BI 1015550 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• Our in-depth analysis of the forecasted sales data of BI 1015550 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BI 1015550 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).

Key Questions

• What is the product type, route of administration, and mechanism of action of BI 1015550?
• What is the clinical trial status of the study related to BI 1015550 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF), and the study completion date?
• What are the key collaborations, mergers, acquisitions, licensing, and other activities related to the BI 1015550 development?
• What are the key designations that have been granted to BI 1015550 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?
• What is the forecasted market scenario of BI 1015550 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?
• What are the forecasted sales of BI 1015550 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to BI 1015550 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?
• Which are the late-stage emerging therapies under development for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?